Pub Date : 2024-11-08DOI: 10.1007/s11696-024-03790-y
Soma Khan, Khalid Khan, Tanzeel Shah, Haroon ur Rashid, Nasir Ahmad, Akhtar Muhammad, Muhammad Zahoor, Muhammad Naveed Umar, Riaz Ullah, Zafar Iqbal
Globally, cancer is the second leading cause of mortality, surpassed only by cardiovascular disorders. Among its various types, Non-Small Cell Lung Cancer (NSCLC) poses a significant global health risk. Chemotherapy is the most common therapeutic approach for treating cancer. However, chemotherapeutic drugs can cause serious toxicity by reducing the survival of both tumor and normal cells, thereby diminishing the survival chances of patients. Natural products extracted from medicinal plants serve as effective anticancer agents with minimal side effects. Among natural compounds, flavonoids have been reported as effective anticancer agents. In this study, two flavonoids, viscosine and quercetin 7-rutinoside, were evaluated for their antitumor potential using in silico models. These flavonoids were tested for their inhibitory activity against DEAD-box RNA helicase DDX3X (referred to as DDX3) and B-cell lymphoma-extra-large (Bcl-XL) enzymes through molecular docking and dynamic simulation analyses. The docking analysis revealed low docking scores and binding energies for both viscosine and quercetin 7-rutinoside. The overall docking results revealed that the selected flavonoids exhibited a favorable binding affinity for DDX3 and Bcl-XL. They bind firmly to the key active sites and remain stably within the pocket regions of DDX3 and Bcl-XL, thereby inhibiting their activity. This data was further supported by the RMSF and RMSD analyses. The preliminary molecular docking and simulation analyses confirm the promising inhibitory effects of viscosine and quercetin 7-rutinoside against DDX3 and Bcl-XL. Therefore, these flavonoids could serve as potential antitumor drug candidates in the future. However, further experimental studies are needed to validate their potential for clinical trials.
{"title":"In silico evaluation of the potential anticancer effects of Viscosine and Quercetin 7-rutinoside: inhibition of DEAD-box RNA helicase DDX3X and b-cell lymphoma-extra large (Bcl-XL) activity","authors":"Soma Khan, Khalid Khan, Tanzeel Shah, Haroon ur Rashid, Nasir Ahmad, Akhtar Muhammad, Muhammad Zahoor, Muhammad Naveed Umar, Riaz Ullah, Zafar Iqbal","doi":"10.1007/s11696-024-03790-y","DOIUrl":"10.1007/s11696-024-03790-y","url":null,"abstract":"<div><p>Globally, cancer is the second leading cause of mortality, surpassed only by cardiovascular disorders. Among its various types, Non-Small Cell Lung Cancer (NSCLC) poses a significant global health risk. Chemotherapy is the most common therapeutic approach for treating cancer. However, chemotherapeutic drugs can cause serious toxicity by reducing the survival of both tumor and normal cells, thereby diminishing the survival chances of patients. Natural products extracted from medicinal plants serve as effective anticancer agents with minimal side effects. Among natural compounds, flavonoids have been reported as effective anticancer agents. In this study, two flavonoids, viscosine and quercetin 7-rutinoside, were evaluated for their antitumor potential using in silico models. These flavonoids were tested for their inhibitory activity against DEAD-box RNA helicase DDX3X (referred to as DDX3) and B-cell lymphoma-extra-large (Bcl-XL) enzymes through molecular docking and dynamic simulation analyses. The docking analysis revealed low docking scores and binding energies for both viscosine and quercetin 7-rutinoside. The overall docking results revealed that the selected flavonoids exhibited a favorable binding affinity for DDX3 and Bcl-<b>X</b><sub><b>L</b></sub>. They bind firmly to the key active sites and remain stably within the pocket regions of DDX3 and Bcl-<b>X</b><sub><b>L</b></sub>, thereby inhibiting their activity. This data was further supported by the RMSF and RMSD analyses. The preliminary molecular docking and simulation analyses confirm the promising inhibitory effects of viscosine and quercetin 7-rutinoside against DDX3 and Bcl-<b>X</b><sub><b>L</b></sub>. Therefore, these flavonoids could serve as potential antitumor drug candidates in the future. However, further experimental studies are needed to validate their potential for clinical trials.</p></div>","PeriodicalId":513,"journal":{"name":"Chemical Papers","volume":"78 18","pages":"9615 - 9626"},"PeriodicalIF":2.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.1007/s11696-024-03791-x
Anupam Yadav, Ashwani Kumar, Junainah Abd Hamid, I. A. Ariffin, Nada Khairi Younis, Mohammed Ahmed Mustafa, Ghadir Kamil Ghadir, Avvaru Praveen Kumar, Abdullah K. Alanazi
Non-benzodiazepine sedative-hypnotic zaleplon has showed potential in reducing symptoms of HIV infection in people who suffer from sleeplessness. It interacts with Gamma-aminobutyric acid (GABA) receptors and enhances sleep quality. Insomnia is associated with metabolic difficulties; zaleplon’s effects on metabolic alterations and branched-chain amino acid (BCAA) metabolism indicate it may be useful in treating these concerns. It also helps with secondary depression, demonstrating its therapeutic value. To evaluate the oral bioavailability and subjective sleep quality and duration of the newly designed Zaleplon nanoemulsifying drug delivery system (SNEDDS). This study developed a solution of optimised Zaleplon self-nanoemulsifying medication delivery devices and then pharmacokinetics and pharmacodynamics characteristics were compared with that of the market-available similar drug on psychiatric patients. Multiple components were obtained, and response surface design reduced tests. The UV–Vis spectrophotometry assessed optical clarity after dilution. Comparing Zal-SNEDDS to control capsules in simulated stomach fluid for dissolution examined medication concentration. High-performance liquid chromatography was used to measure serum Zaleplon concentration before and after administration. The study demonstrated significant improvements in subjective sleep quality for the Zaleplon-SNEDDS group, which scored lower (0.69 ± 0.066) compared to the usual Zaleplon group (1.25 ± 0.085) with a p-value of 0.0026. Sleep latency showed no significant difference between the groups. Both groups had low sleep disturbance scores, with no significant difference observed. Daytime dysfunction significantly improved in the Zaleplon-SNEDDS group (p = 0.0012). Sleep duration was significantly better in the Zaleplon-SNEDDS group (p = 0.045). Total PSQI scores showed a trend towards improvement in the Zaleplon-SNEDDS group, though not statistically significant (p = 0.065). The study concluded that Zaleplon-SNEDDS is highly effective in increasing subjective sleep quality, daytime dysfunction and sleep duration as compared to the Zaleplon available in the market.
{"title":"Evaluation of oral bioavailability and other pharmacy effects on sleep quality by using zaleplon nano emulsifying drug delivery systems carrying","authors":"Anupam Yadav, Ashwani Kumar, Junainah Abd Hamid, I. A. Ariffin, Nada Khairi Younis, Mohammed Ahmed Mustafa, Ghadir Kamil Ghadir, Avvaru Praveen Kumar, Abdullah K. Alanazi","doi":"10.1007/s11696-024-03791-x","DOIUrl":"10.1007/s11696-024-03791-x","url":null,"abstract":"<div><p>Non-benzodiazepine sedative-hypnotic zaleplon has showed potential in reducing symptoms of HIV infection in people who suffer from sleeplessness. It interacts with Gamma-aminobutyric acid (GABA) receptors and enhances sleep quality. Insomnia is associated with metabolic difficulties; zaleplon’s effects on metabolic alterations and branched-chain amino acid (BCAA) metabolism indicate it may be useful in treating these concerns. It also helps with secondary depression, demonstrating its therapeutic value. To evaluate the oral bioavailability and subjective sleep quality and duration of the newly designed Zaleplon nanoemulsifying drug delivery system (SNEDDS). This study developed a solution of optimised Zaleplon self-nanoemulsifying medication delivery devices and then pharmacokinetics and pharmacodynamics characteristics were compared with that of the market-available similar drug on psychiatric patients. Multiple components were obtained, and response surface design reduced tests. The UV–Vis spectrophotometry assessed optical clarity after dilution. Comparing Zal-SNEDDS to control capsules in simulated stomach fluid for dissolution examined medication concentration. High-performance liquid chromatography was used to measure serum Zaleplon concentration before and after administration. The study demonstrated significant improvements in subjective sleep quality for the Zaleplon-SNEDDS group, which scored lower (0.69 ± 0.066) compared to the usual Zaleplon group (1.25 ± 0.085) with a p-value of 0.0026. Sleep latency showed no significant difference between the groups. Both groups had low sleep disturbance scores, with no significant difference observed. Daytime dysfunction significantly improved in the Zaleplon-SNEDDS group (<i>p</i> = 0.0012). Sleep duration was significantly better in the Zaleplon-SNEDDS group (<i>p</i> = 0.045). Total PSQI scores showed a trend towards improvement in the Zaleplon-SNEDDS group, though not statistically significant (<i>p</i> = 0.065). The study concluded that Zaleplon-SNEDDS is highly effective in increasing subjective sleep quality, daytime dysfunction and sleep duration as compared to the Zaleplon available in the market.</p></div>","PeriodicalId":513,"journal":{"name":"Chemical Papers","volume":"78 18","pages":"9627 - 9642"},"PeriodicalIF":2.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.1007/s11696-024-03785-9
Sher Zaman Safi, Sadia Fazil, Laiba Saeed, Humaira Shah, Muhammad Arshad, Hussah M. Alobaid, Fozia Rehman, Faiza Sharif, Chandrabose Selvaraj, Abdul Hamid Orakzai, Muhammad Tariq, Antony V. Samrot, Abdul Qadeer, Abid Ali, Kalaivani Batumalaie, Vetriselvan Subramaniyan, Shah Alam Khan, Ikram Shah Bin Ismail
Chitosan and heparin are two biopolymers with different properties that can be combined to develop biomaterials with unique and desirable characteristics. Chitosan is a cationic polymer with antimicrobial, hemostatic, and wound-healing properties. Heparin is an anionic polymer with anticoagulant properties. The combination of chitosan and heparin can be used to develop biomaterials with a variety of applications, including drug delivery, wound dressing, and tissue engineering. These biomaterials can be fabricated into various forms, such as films, membranes, sponges, hydrogels, nanoparticles, and scaffolds. Chitosan is a natural polysaccharide, present in the form of copolymers of N-acetyl-D-glucosamine as repeating units. Heparin is a natural glycosaminoglycan; a linear sulfated molecule consisting of repetitive units of disaccharide containing uronic acid and N-acetyl glucosamine. Heparin binds and activates the vascular endothelial growth factor (VEGF), which in turn promotes proliferation and migration and thus results in angiogenesis and the formation of new blood vessels. These advantages make chitosan- and heparin-based biomaterials promising candidates for a variety of biomedical applications. However, there are still some challenges that need to be addressed before these biomaterials can be widely used in clinical practices. For example, the degradation rate of chitosan- and heparin-based biomaterials need to be better controlled, and the mechanical properties of these biomaterials need to be improved. Despite these challenges, chitosan- and heparin-based biomaterials have the potential to revolutionize the field of biomedicine. These biomaterials offer several advantages over traditional materials, and they have the potential to be used in a variety of innovative applications. The purpose of this review is to provide a comprehensive overview of the current state of research and applications in this field. It aims to summarize the key findings and advancements in the development and use of chitosan- and heparin-based hydrogels for various biomedical applications.
{"title":"Chitosan- and heparin-based advanced hydrogels: their chemistry, structure and biomedical applications","authors":"Sher Zaman Safi, Sadia Fazil, Laiba Saeed, Humaira Shah, Muhammad Arshad, Hussah M. Alobaid, Fozia Rehman, Faiza Sharif, Chandrabose Selvaraj, Abdul Hamid Orakzai, Muhammad Tariq, Antony V. Samrot, Abdul Qadeer, Abid Ali, Kalaivani Batumalaie, Vetriselvan Subramaniyan, Shah Alam Khan, Ikram Shah Bin Ismail","doi":"10.1007/s11696-024-03785-9","DOIUrl":"10.1007/s11696-024-03785-9","url":null,"abstract":"<div><p>Chitosan and heparin are two biopolymers with different properties that can be combined to develop biomaterials with unique and desirable characteristics. Chitosan is a cationic polymer with antimicrobial, hemostatic, and wound-healing properties. Heparin is an anionic polymer with anticoagulant properties. The combination of chitosan and heparin can be used to develop biomaterials with a variety of applications, including drug delivery, wound dressing, and tissue engineering. These biomaterials can be fabricated into various forms, such as films, membranes, sponges, hydrogels, nanoparticles, and scaffolds. Chitosan is a natural polysaccharide, present in the form of copolymers of N-acetyl-D-glucosamine as repeating units. Heparin is a natural glycosaminoglycan; a linear sulfated molecule consisting of repetitive units of disaccharide containing uronic acid and N-acetyl glucosamine. Heparin binds and activates the vascular endothelial growth factor (VEGF), which in turn promotes proliferation and migration and thus results in angiogenesis and the formation of new blood vessels. These advantages make chitosan- and heparin-based biomaterials promising candidates for a variety of biomedical applications. However, there are still some challenges that need to be addressed before these biomaterials can be widely used in clinical practices. For example, the degradation rate of chitosan- and heparin-based biomaterials need to be better controlled, and the mechanical properties of these biomaterials need to be improved. Despite these challenges, chitosan- and heparin-based biomaterials have the potential to revolutionize the field of biomedicine. These biomaterials offer several advantages over traditional materials, and they have the potential to be used in a variety of innovative applications. The purpose of this review is to provide a comprehensive overview of the current state of research and applications in this field. It aims to summarize the key findings and advancements in the development and use of chitosan- and heparin-based hydrogels for various biomedical applications.</p></div>","PeriodicalId":513,"journal":{"name":"Chemical Papers","volume":"78 18","pages":"9287 - 9309"},"PeriodicalIF":2.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-08DOI: 10.1007/s11696-024-03765-z
Ume Salma, Raheela Sharafat, Zunaira Zafar, Faisal Nawaz, Gul Shahzada Khan, Sarah A. Alsalhi, Shaimaa A. M. Abdelmohsen, Javed Iqbal
{"title":"Correction: A theoretical approach for investigating the end-capped engineering effect on indophenine-based core for efficient organic solar cells","authors":"Ume Salma, Raheela Sharafat, Zunaira Zafar, Faisal Nawaz, Gul Shahzada Khan, Sarah A. Alsalhi, Shaimaa A. M. Abdelmohsen, Javed Iqbal","doi":"10.1007/s11696-024-03765-z","DOIUrl":"10.1007/s11696-024-03765-z","url":null,"abstract":"","PeriodicalId":513,"journal":{"name":"Chemical Papers","volume":"78 17","pages":"9003 - 9003"},"PeriodicalIF":2.2,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142736998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-07DOI: 10.1007/s11696-024-03760-4
Eman Alzahrani, Baher I. Salman, Ahmed I. Hassan, Ahmed Al-Harrasi, Adel Ehab Ibrahim, Abd-ElAziem Farouk, Mohamed A. Abdel-Lateef
The health crisis induced by the COVID-19 pandemic has accelerated the quest for innovative antiviral drugs. One such advancement is the authorization of favipiravir (FAR) as an antiviral medication for COVID-19 management. As a result, it is essential to develop precise and cost-effective methodologies for quantifying FAR levels in plasma samples and tablets. In this research, we describe the creation of novel, thermostable (25–80 °C) and pH (3–11) stable amine-doped carbon dots (N@CQDs using green source) produced via a single-step synthesis approach for the assessment of FAR with high quantum yield 33.84% for reduction in the consumed organic solvents. Carbon quantum dots (CQDs) have garnered significant attention in recent times due to their effectiveness as probes. Their affordability, environmentally friendly nature, and exceptional photocatalytic properties have positioned them as noteworthy substitutes for traditional luminescent methods such as fluorescent dyes and luminous derivatization. The addition of FAR significantly reduced the luminescence response of the synthesized green and stable carbon quantum dots at 515 nm. The linear graph for detection was quantified to be 5.0–200.0 ng mL−1, with a lower limit of quantitation (LOQ) of 3.85 ng mL−1. The method’s high sensitivity, thermostable, and selectivity make it suitable for use in clinical laboratories. Besides, the reusability and stability of the N@CQDs were conducted effectively for analysis of FAR.
COVID-19 大流行引发的健康危机加速了对创新抗病毒药物的探索。其中一项进展就是授权使用法非拉韦(FAR)作为抗病毒药物来治疗 COVID-19。因此,开发精确且经济有效的方法来量化血浆样本和药片中的 FAR 水平至关重要。在这项研究中,我们介绍了通过单步合成方法制备的新型、恒温(25-80 °C)和 pH 值(3-11)稳定的胺掺杂碳点(N@CQDs,使用绿色源),用于评估 FAR,其量子产率高达 33.84%,减少了有机溶剂的消耗。近年来,碳量子点(CQDs)因其作为探针的有效性而备受关注。碳量子点价格低廉、环境友好、光催化性能优异,因此成为荧光染料和发光衍生化等传统发光方法的理想替代品。加入 FAR 后,合成的绿色稳定碳量子点在 515 纳米波长处的发光响应明显降低。检测线性图为 5.0-200.0 ng mL-1,定量下限(LOQ)为 3.85 ng mL-1。该方法灵敏度高、恒温性好、选择性强,适用于临床实验室。此外,N@CQDs 的可重复使用性和稳定性在分析 FAR 中也得到了有效的验证。
{"title":"Harnessing new and stable green carbon nanoprobes enables a selective and reliable approach to fluorimetric analysis of favipiravir drug in human plasma","authors":"Eman Alzahrani, Baher I. Salman, Ahmed I. Hassan, Ahmed Al-Harrasi, Adel Ehab Ibrahim, Abd-ElAziem Farouk, Mohamed A. Abdel-Lateef","doi":"10.1007/s11696-024-03760-4","DOIUrl":"10.1007/s11696-024-03760-4","url":null,"abstract":"<div><p>The health crisis induced by the COVID-19 pandemic has accelerated the quest for innovative antiviral drugs. One such advancement is the authorization of favipiravir (FAR) as an antiviral medication for COVID-19 management. As a result, it is essential to develop precise and cost-effective methodologies for quantifying FAR levels in plasma samples and tablets. In this research, we describe the creation of novel, thermostable (25–80 °C) and pH (3–11) stable amine-doped carbon dots (N@CQDs using green source) produced via a single-step synthesis approach for the assessment of FAR with high quantum yield 33.84% for reduction in the consumed organic solvents. Carbon quantum dots (CQDs) have garnered significant attention in recent times due to their effectiveness as probes. Their affordability, environmentally friendly nature, and exceptional photocatalytic properties have positioned them as noteworthy substitutes for traditional luminescent methods such as fluorescent dyes and luminous derivatization. The addition of FAR significantly reduced the luminescence response of the synthesized green and stable carbon quantum dots at 515 nm. The linear graph for detection was quantified to be 5.0–200.0 ng mL<sup>−1</sup>, with a lower limit of quantitation (LOQ) of 3.85 ng mL<sup>−1</sup>. The method’s high sensitivity, thermostable, and selectivity make it suitable for use in clinical laboratories. Besides, the reusability and stability of the N@CQDs were conducted effectively for analysis of FAR.</p></div>","PeriodicalId":513,"journal":{"name":"Chemical Papers","volume":"78 18","pages":"9485 - 9496"},"PeriodicalIF":2.2,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142737024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-11-06DOI: 10.1007/s11696-024-03769-9
Siyuan Wang, Wenchao Zhang, Han Qin, Meidi Luo, Rui Lin, Jiachen Wen, Dan Liu
TMP195 is a highly profiled clinical candidate demonstrating class IIa histone deacetylase (HDAC) selective inhibition. Current preparation of TMP195 is limited to subgram-scale due to the requirement of tedious (post-)experimental procedures and the uses of hazardous reagents. To fulfill the unmet need for the bulky synthesis of TMP195 for the future clinical study, we have carried out its synthetic research. The present study provides a novel synthetic process suitable for the multigram-scale synthesis of TMP195. Its overall yield has increased significantly from the literature to the present, with respective values of 9% and 45%. Notably, the proposed process is more efficient and facile, characterized by accelerated reaction rates from 40 h to within 19 h and a streamlined post-reaction column chromatography purification from five reactions to just one. Additionally, the proposed process is more environmentally friendly, featured by the solvent-free synthesis of key intermediate 4-(chloromethyl)-2-phenyloxazole and replacement of non-toxic cyanide source. This newly proposed synthetic process is highly stable and repeatable under 10 gramme scale counted by benzamide as starting material.